AstraZeneca's experimental stomach cancer drug doubles survival in advanced clinical trial

AstraZeneca announced that its experimental drug "Sonesitatug Vedotin" (SON-V) showed promising results in an advanced clinical trial for patients with advanced stomach cancer who had received prior treatments. Sources reported that it raised median survival from 5 to 10 months and reduced the risk of death by 53%, while an international source reported a reduction of more than 40%.

AI-written summary of 14 sources; every verified point is backed by a verbatim quote. How Iyan works

• The drug is linked to chemotherapy in the trial, and it raised median survival from 5 to 10 months.

  «الجمع بين العقار التجريبي والعلاج الكيميائي رفع متوسط البقاء على قيد الحياة من 5 إلى 10 أشهر.»

  شبكة التلفزيون العربي
• Local coverage reported that the drug reduces the risk of death by 53% compared with chemotherapy.

  «يرفع متوسط البقاء إلى 10 أشهر مقابل 5 أشهر للعلاج الكيماوي ويخفض خطر الوفاة 53 %»

  صحيفة سبق الالكترونية
• International coverage described the drug as an antibody-drug conjugate and said it doubled median overall survival.

  «دواء أسترازينيكا التجريبي من نوع مضادات الأجسام المقترنة بالأدوية تضاعف متوسط البقاء الإجمالي في تجربة متقدمة»

  NDTV on MSN
• An international source reported that the drug extended overall survival by about five months.

  «مد البقاء الإجمالي نحو خمسة أشهر، وقارب ضعف البقاء لمرضى سرطان المعدة المتقدم.»

  Independent Journal Review
• Another international source reported that the drug reduces the risk of death by more than 40%.

  «يخفض خطر الوفاة لدى مرضى سرطان المعدة المتقدم بأكثر من 40%.»

  Health and Me

Iyan — See it for yourself. What changed in your world today, why it matters, and how we know.
How it works • Privacy • Terms